On November 3, the 2022 China Biotechnology Innovation Conference opened. At the meeting, the China Biotechnology Development Center of the Ministry of Science and Technology of China released the "2022 China Biopharmaceutical Industrial Park Development Competitiveness Evaluation and Analysis Report", and the "2021 China Biopharmaceutical Park Development Competitiveness Ranking" was also announced simultaneously.
"2021 China Biomedical Park Development Competitiveness Ranking" is divided into "Park Comprehensive Competitiveness Ranking" and "Park Single Competitiveness Ranking". Single competitiveness is divided into five aspects: environmental competitiveness, industrial competitiveness, technical competitiveness, talent competitiveness and cooperative competitiveness.
Among them, in the comprehensive competitiveness ranking of the park, Chengdu Hi-tech Zone ranked third, up one place from last year, ranking first with Beijing Zhongguancun and Suzhou Industrial Park; in the park's single-item ranking, the three first-level indicators of industrial competitiveness, technical competitiveness and environmental competitiveness are all ranked in the top three.
It is reported that since 2013, the China Biotechnology Development Center has conducted 8 evaluations and analysis of the development competitiveness of biopharmaceutical industry parks, and continues to release the development of the biopharmaceutical parks. This center has ranked various competitiveness in 109 national high-tech zones, 84 national economic and technological development zones, 18 provincial and other parks.
Create a project cluster
Promote industrial construction and strengthening chain
As the main battlefield of Chengdu’s industrial development, Chengdu Hi-tech Zone focuses on building a circle and strengthening chain around the industry, giving full play to the role of fund investment promotion, continuously improving and strengthening the biopharmaceutical industry level, and accelerating the high-quality development of the biopharmaceutical industry . Up to now, Chengdu Hi-tech Zone has guided the establishment of 5 medical and health sub-funds, with a cumulative scale of fund reaching 6.6 billion. This year, it has promoted the successful implementation of more than 10 companies through fund investment.
Just last week, the Fortune 500 General Electric (GE) Medical China Precision Medical Industrial Base Project was signed and implemented. This is the first industrial base built by the Fortune 500 medical companies in Sichuan to acquire land and build itself. It is also the first industrial project of GE Medical to enter western China.
Currently, Chengdu Hi-tech Zone is focusing on project clusters such as "Tianfu Vaccine Valley", "National Largest Own Varieties Anti-drug Production Base", and "Asia's Largest Blood Products Production Base", and other projects, and is striving to build a modern industrial system with regional driving force and development competitiveness.
Red Star News reporter learned that the Yiqiao innovative drug production base with a total investment of 7 billion yuan has entered the trial operation stage and can support more than 10 antibody drugs for local production, and will become China's largest independent innovative variety antibody drug production base; Rongsheng blood products production base has entered the trial production stage and will be built into Asia's largest and leading blood products industry base with technical equipment.
Chengdu Frontier Medical Center
Multiple products have been approved for marketing
Continuously enhancing the innovation source of the biological industry
In Chengdu Frontier Medical Center located in Xinchuan Industrial Park, Chengdu Hi-tech Zone, the only national precision medicine industry innovation center in the country is located here. As the first national-level industrial innovation center in Sichuan Province, the center has planned 8 platforms including gene detection , molecular diagnosis, cell therapy, targeted drug research and development, immortal cell resource library, individualized drug screening center, and intellectual property operation center. It is accelerating the decoration of the E4 carrier of the Phase 1 of Frontier Medical Center and completing equipment procurement, striving to officially operate within the year.
In addition, the research and development and production of enterprises in Chengdu Hi-tech Zone are constantly moving forward, and a number of innovative achievements have emerged. In September this year, Iodpromide Injection, a contrast agent product developed by Bet Pharmaceutical for four years, was approved for marketing, becoming the first generic drug of this variety in China. This move broke the monopoly of the original imported drugs in the domestic market for more than 20 years; in October, the immunosuppressant tacrolimus sustained release capsule developed and produced by Shengdi Pharmaceutical was first launched, and is the first generic drug of this variety in China, which can be used to treat graft rejection reactions that cannot be controlled by other immunosuppressive drugs after kidney or liver transplantation.Huang Haoxi, director of the
bet Pharmaceutical Research Institute, said, "Contrast agents are only one of the products developed by the company. Currently, there are more than 230 other products under development, including many cutting-edge technology projects in the future. We strive to master more key core technologies in the future."
bet Pharmaceutical Research and Development Staff conducted experiments
As of now, Chengdu Hi-Tech Zone has a total of 141 new drugs under development, and more than 50 are in the clinical stage. It has promoted the domestic approval of Jianjin Pharmaceutical's first China-US dual-report product for injection mycophenolate in China to be approved for marketing; Chengdu Weishi Medical's first digestive endoscopic AI-assisted diagnostic product EndoScreener in China to be approved for marketing.
In addition, Chengdu Hi-tech Zone has steadily promoted the listing process of biomedical enterprises, with a total of 10 listed and approved companies, and has reserved 23 companies that intend to be listed, including West China Haiqi.
Red Star News Reporter Peng Xiangping
Edit Chen Yixi
(Download Red Star News , report the prize!)
